Science

$Benny Johnson: BOT/BAL in chemotherapy refractory MSS mCRC with no active liver metastases$

Benny Johnson

Jan 27, 2025, 08:22

Benny Johnson: BOT/BAL in chemotherapy refractory MSS mCRC with no active liver metastases

Benny Johnson, Senior Medical Director at Agenus, shared his recent article on LinkedIn:

“Don’t miss our rapid oral presentation today ASCO GI- Results of a global Phase 2 study of BOT/BAL in chemotherapy refractory MSS mCRC with no active liver metastases presented by Marwan Fakih.

In this 5 arm study that enrolled 234 pts, the combination arm of BOT 75 + BAL achieved a 19% ORR and 55% DCR, meeting the primary endpoint of the study.

There were 0 responses with the SOC arm. BOT 75 combo is active, safe & selected for upcoming Phase 3 trials.”

Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM).

Authors: Marwan Fakih, et al.

$Benny Johnson: BOT/BAL in chemotherapy refractory MSS mCRC with no active liver metastases$

Agenus ASCO Balstilimab Benny Johnson botensilimab cancer chemotherapy fight against cancer Global fight against cancer Marwan Fakih mCRC Metastatic colorectal cancer OncoDaily Oncology

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more